Skip to main content

PHVS · Pharvaris N.V.

Track PHVS — free
$31.67 +0.01 (+0.03%)
Market Cap
$2.24B
Shares
70.79M
Volume · Nov 20 214.7K Avg daily vol (3M) 755.25K

Price & Indicators

 

Key stats

Close
$31.66
Thu 19 Nov
Open
$31.74
Thu 19 Nov
Average volume, 30 days
582K
shares a session
Short interest
2.5M
3.6% of shares · 3.6 days to cover
Day range
$31.45$32.44
Open $31.74 Close $31.66
52-week closing range
$23.68$38.86
Close $31.66 18.5% under the high
Short volume, last session
57%
Price history
Feb 2021 to Nov 2026

Latest documents

2026
Nov 12
Current report 6-K
Deucrictibant FDA review targets April 23, 2027

Pharvaris reported the FDA PDUFA target action date for deucrictibant IR is April 23, 2027; CREAATE part 1 topline data are expected in 1Q2027. Cash and cash equivalents were €283 million, and quarterly loss was €47.4 million.

Read from the first part of this long document
5 source passages
Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23, 2027 Topline data from part 1 of CREAATE, a pivotal Phase 3 study evaluating deucrictibant XR for the prophylaxis of AAE-C1INH attacks, expected in 1Q2027 Cash and cash equivalents were €283 million as of September 30, 2026, compared to €292 million for December 31, 2025. Loss for the quarter. Loss for the third quarter was €47.4 million, resulting in basic and diluted loss per share of €0.67 for the quarter ended September 30, 2026, compared to €37.1 million, or basic and diluted loss per share of €0.60, for the quarter ended September 30, 2025. Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema (AE-BK), such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced financial results for the third quarter ending on September 30, 2026, and provided a business update. Open the document at this passage
Nov 9
Investor event
On-demand PDUFA date set for April 23rd, 2027

Pharvaris N.V. has an April 23rd, 2027 PDUFA date for on-demand treatment, plans CREATE topline data in the first quarter of next year, and expects parallel prophylaxis NDAs after collecting safety data in the first half of the 27th year.

3 source passages
We have a PIDUFA date for that on April 23rd, 2027. we're also going to be reading out top-line data from our CREATE study, which is the do correct demand for the prevention of acquired angioedema attacks. That'll be in the first quarter of next year. We expect we collect all the data, the first half of the 27th year, then we can submit that, you know, the NDA filing for the prophylaxis. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-8.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+19.9%
Year over year · more shares
Price change (1Y)
+29.0%
Trailing year
Short interest
3.6%
Latest settlement · 3.6 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.62
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +1%
above
Price vs 50-day avg −4%
below
RSI (14) 43
neutral
MACD trend Negative
52-week position 53%
mid-range
Momentum
relative strength
Very Strong
1-month return +3%
trailing
6-month return +9%
trailing
YTD return +14%
this year
Relative strength +14%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $33 › 200d $31 — 50d above 200d
Institutional flow Accumulating
+10% holders QoQ · +24 funds added
Insider flow Distributing
Net -$16.2M over 90 days · 100% sells
Short interest Rising
3.59% of shares out · ▲ +3.0% MoM · 3.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
137 holders — near 3-yr high, broad support
Squeeze score 53
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 53%
annualized · 1-yr
Max drawdown −29%
past year
ATR 4.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+1% Bullish
Price vs 50-day avg
−4% Neutral
RSI (14)
43 Neutral
MACD trend
Negative Bearish
52-week position
53% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $33 › 200d $31 — 50d above 200d
Institutional flow Accumulating
+10% holders QoQ · +24 funds added
Insider flow Distributing
Net -$16.2M over 90 days · 100% sells
Short interest Rising
3.59% of shares out · ▲ +3.0% MoM · 3.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
137 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $24 Now $32 · 53% Range high $39
vs 200-day avg +1% vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PHVS
Pharvaris N.V.
this stock
$2.24B +14.1% — — 3.6%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
137
% held
94.9%
Net QoQ
+2.6M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
15
View
Short & Settlement
Short Interest Rising
Shares short
2.5M
Days to cover
3.6d
Change
+74.1K sh
View
Short Volume
Short vol %
57%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
1.0K
Value
$32.0K
As of
Oct 1, 2026
View
Off-Exchange
Off-exchange %
54.7%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$16.2M
Buyers / Sellers
0 / 8
Buyers Sellers
View
Filings
SEC Filings
Latest
6-K
Filed
Nov 12, 2026
This year
16

Pharvaris reported the FDA PDUFA target action date for deucrictibant IR is April 23, 2027; CREAATE part 1 topline data are expected in 1Q2027. Cash and cash equivalents were €283 million, and quarterly loss was €47.4 million.

View
Proposed Sales
Value
$395.5K
Shares
12.0K
Filed
Sep 23, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 1, 2026
Last webcast
Nov 9, 2026
View
Investor Relations
Upcoming events
4
View

Performance

5D 20D 120D MTD YTD
PHVS -6.4% +3.2% +8.8% -5.6% +14.1%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -1.0% +9.5% +14.4% -0.3% +9.1%
Key facts CIK 1830487 CUSIP N69605108 13F (30d) 150 filings 134 filers Visit website Investor relations